Suppr超能文献

对于晚期癌症患者,是否应根据患者特征调整控释羟考酮的剂量?

Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?

出版信息

Support Care Cancer. 2014 Feb;22(2):325-30. doi: 10.1007/s00520-013-1973-6.

Abstract

PURPOSE

This study aimed to investigate whether the characteristics of patients with advanced cancer explain the variability in oxycodone clearance, with the potential for this information to determine maintenance dosing.

METHODS

Patients (n = 36) with advanced cancer who were receiving delayed-release oxycodone (Oxycontin®) (mean dose, 31.4 mg; range, 5-120 mg) mostly twice daily (mean duration = 80 days; range, 5-651 days) provided venous blood samples (n = 139, median = 3 per patient) drawn from 0.25 to 23.4 h post-dose. Plasma was assayed for oxycodone (mean = 39.4 ng/mL; range, 1-256 ng/mL) by high-performance liquid chromatography with tandem mass spectrometry detection. Pharmacokinetic modeling was performed using nonlinear mixed-effects modeling (NONMEM).

RESULTS

A one-compartment model with first-order absorption and elimination best described the data. Typical population values and between-subject variability (coefficient of variation, percent) for oxycodone clearance and the oral absorption rate constant were 73 L/h (31.9 %) and 0.0735 h (133 %), respectively. The volume of distribution was estimated based on literature values for intravenous oxycodone in cancer patients. The inclusion of weight, sex, age, creatinine clearance, and serum albumin concentration did not significantly explain pharmacokinetic variability in clearance or absorption rate constant. The subject with the most elevated liver function test values also had the lowest clearance per kilogram.

CONCLUSIONS

Oxycodone clearance was similar to that reported previously for healthy adults. Despite reports that patient characteristics significantly affect oxycodone pharmacokinetics, our results do not support alteration of current prescribing practices for maintenance dosing of Oxycontin® in most patients with advanced cancer. The influence of marked liver dysfunction on oxycodone clearance requires further investigation.

摘要

目的

本研究旨在探讨晚期癌症患者的特征是否能解释羟考酮清除率的变异性,从而为确定维持剂量提供信息。

方法

接受延迟释放羟考酮(Oxycontin®)(平均剂量 31.4mg;范围 5-120mg)治疗的晚期癌症患者(n=36)大多每日两次(平均持续时间 80 天;范围 5-651 天),从给药后 0.25 至 23.4 小时内采集静脉血样(n=139,中位数为每个患者 3 次)。采用高效液相色谱-串联质谱法检测羟考酮(平均 39.4ng/ml;范围 1-256ng/ml)。采用非线性混合效应模型(NONMEM)进行药代动力学建模。

结果

吸收和消除呈一室模型的一阶模型最能描述数据。羟考酮清除率和口服吸收速率常数的典型群体值和个体间变异性(变异系数,%)分别为 73L/h(31.9%)和 0.0735h(133%)。根据癌症患者静脉内羟考酮的文献值估计了分布容积。体重、性别、年龄、肌酐清除率和血清白蛋白浓度的纳入并未显著解释清除率或吸收速率常数的药代动力学变异性。肝功能试验值最高的受试者的清除率也最低。

结论

羟考酮清除率与先前报道的健康成年人相似。尽管有报道称患者特征显著影响羟考酮的药代动力学,但我们的结果不支持对大多数晚期癌症患者的 Oxycontin®维持剂量进行当前的调整。严重肝功能障碍对羟考酮清除率的影响需要进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验